A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

• Status: Recruiting
• Trial end date: 2026-06-01

Summary

This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.